How many insider trades does FilingIQ track for ONCO?

FilingIQ tracks 26 Form 4 insider transactions for ONCO (Onconetix, Inc.), covering filings from Feb 16, 2024 onwards. 6 of those were filed in the last 90 days.

Are ONCO insiders net buyers or net sellers?

Across the full Form 4 history for ONCO, 3 transactions (12%) were open-market purchases and 3 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ONCO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ONCO in?

Onconetix, Inc. (ONCO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $545163.

ONCO insider trading

NasdaqCM Healthcare

Onconetix, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

12% / 12%

Market cap

$545163

About Onconetix, Inc.

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Company website: www.onconetix.com

ONCO insider activity at a glance

FilingIQ has scored 26 insider transactions for ONCO since Feb 16, 2024. The most recent filing in our index is dated Apr 21, 2026.

Across the full history, 3 open-market purchases and 3 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ONCO insider trades is 59.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ONCO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ONCO?: FilingIQ tracks 26 Form 4 insider transactions for ONCO (Onconetix, Inc.), covering filings from Feb 16, 2024 onwards. 6 of those were filed in the last 90 days.
Are ONCO insiders net buyers or net sellers?: Across the full Form 4 history for ONCO, 3 transactions (12%) were open-market purchases and 3 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ONCO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ONCO in?: Onconetix, Inc. (ONCO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $545163.

Methodology & sources

Every ONCO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.